valbenazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5227 | 1025504-45-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The mechanism of action of valbenazine in the treatment of tardive dyskinesia is unknown, but is thought to be mediated through the reversible inhibition of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 1.31 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.71 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 18 hours | Lombardo F, Berellini G, Obach RS |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 11, 2017 | FDA | NEUROCRINE BIOSCIENCES INC | |
| March 28, 2022 | PMDA | Mitsubishi Tanabe Pharma Corporation |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Somnolence | 479.52 | 35.01 | 250 | 4951 | 178435 | 63305386 |
| Drooling | 391.32 | 35.01 | 85 | 5116 | 3783 | 63480038 |
| Tremor | 292.00 | 35.01 | 163 | 5038 | 132076 | 63351745 |
| Parkinsonism | 275.46 | 35.01 | 78 | 5123 | 10361 | 63473460 |
| Sedation | 224.92 | 35.01 | 93 | 5108 | 38716 | 63445105 |
| Dyskinesia | 183.03 | 35.01 | 76 | 5125 | 31926 | 63451895 |
| Hospitalisation | 140.21 | 35.01 | 87 | 5114 | 84994 | 63398827 |
| Death | 115.36 | 35.01 | 147 | 5054 | 374234 | 63109587 |
| Balance disorder | 97.01 | 35.01 | 69 | 5132 | 84353 | 63399468 |
| Therapeutic product effect decreased | 93.51 | 35.01 | 96 | 5105 | 193091 | 63290730 |
| Akathisia | 88.99 | 35.01 | 32 | 5169 | 9114 | 63474707 |
| Adverse drug reaction | 86.64 | 35.01 | 63 | 5138 | 79651 | 63404170 |
| Restlessness | 86.33 | 35.01 | 44 | 5157 | 29409 | 63454412 |
| Drug ineffective | 85.01 | 35.01 | 230 | 4971 | 1044535 | 62439286 |
| Therapeutic product effect incomplete | 82.96 | 35.01 | 74 | 5127 | 124982 | 63358839 |
| Fall | 67.01 | 35.01 | 117 | 5084 | 392217 | 63091604 |
| Urticaria | 60.33 | 35.01 | 71 | 5130 | 165731 | 63318090 |
| Anxiety | 55.33 | 35.01 | 78 | 5123 | 217463 | 63266358 |
| Feeling abnormal | 54.72 | 35.01 | 64 | 5137 | 148328 | 63335493 |
| Dizziness | 52.20 | 35.01 | 111 | 5090 | 429814 | 63054007 |
| Lethargy | 51.33 | 35.01 | 40 | 5161 | 55967 | 63427854 |
| Nightmare | 48.57 | 35.01 | 26 | 5175 | 19168 | 63464653 |
| Tardive dyskinesia | 47.88 | 35.01 | 20 | 5181 | 8482 | 63475339 |
| Bradykinesia | 46.16 | 35.01 | 17 | 5184 | 5171 | 63478650 |
| Gait disturbance | 45.53 | 35.01 | 65 | 5136 | 183113 | 63300708 |
| Depression | 43.47 | 35.01 | 66 | 5135 | 196426 | 63287395 |
| Fatigue | 40.41 | 35.01 | 161 | 5040 | 887867 | 62595954 |
| Insomnia | 36.34 | 35.01 | 64 | 5137 | 215188 | 63268633 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drooling | 414.64 | 45.50 | 86 | 2599 | 3296 | 34950950 |
| Somnolence | 274.92 | 45.50 | 144 | 2541 | 110972 | 34843274 |
| Parkinsonism | 170.18 | 45.50 | 50 | 2635 | 8088 | 34946158 |
| Tremor | 164.48 | 45.50 | 93 | 2592 | 82494 | 34871752 |
| Sedation | 151.97 | 45.50 | 58 | 2627 | 20948 | 34933298 |
| Hospitalisation | 99.49 | 45.50 | 59 | 2626 | 56843 | 34897403 |
| Therapeutic product effect decreased | 79.50 | 45.50 | 43 | 2642 | 34700 | 34919546 |
| Drug ineffective | 78.43 | 45.50 | 131 | 2554 | 456620 | 34497626 |
| Fall | 67.23 | 45.50 | 80 | 2605 | 202805 | 34751441 |
| Anxiety | 65.67 | 45.50 | 57 | 2628 | 99371 | 34854875 |
| Dyskinesia | 63.41 | 45.50 | 32 | 2653 | 22381 | 34931865 |
| Death | 61.31 | 45.50 | 109 | 2576 | 397940 | 34556306 |
| Adverse drug reaction | 60.71 | 45.50 | 34 | 2651 | 29308 | 34924938 |
| Restlessness | 53.99 | 45.50 | 30 | 2655 | 25452 | 34928794 |
| Dizziness | 50.21 | 45.50 | 72 | 2613 | 218449 | 34735797 |
| Therapeutic product effect incomplete | 46.03 | 45.50 | 35 | 2650 | 50506 | 34903740 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Somnolence | 447.82 | 36.45 | 247 | 5143 | 238734 | 79500264 |
| Drooling | 442.15 | 36.45 | 98 | 5292 | 5836 | 79733162 |
| Tremor | 301.80 | 36.45 | 170 | 5220 | 169913 | 79569085 |
| Parkinsonism | 233.47 | 36.45 | 73 | 5317 | 16511 | 79722487 |
| Sedation | 190.08 | 36.45 | 85 | 5305 | 51810 | 79687188 |
| Death | 149.94 | 36.45 | 187 | 5203 | 566327 | 79172671 |
| Hospitalisation | 147.43 | 36.45 | 87 | 5303 | 94149 | 79644849 |
| Dyskinesia | 143.93 | 36.45 | 67 | 5323 | 44706 | 79694292 |
| Anxiety | 103.12 | 36.45 | 104 | 5286 | 248408 | 79490590 |
| Restlessness | 97.29 | 36.45 | 52 | 5338 | 46440 | 79692558 |
| Fall | 96.53 | 36.45 | 140 | 5250 | 487489 | 79251509 |
| Balance disorder | 85.33 | 36.45 | 63 | 5327 | 98794 | 79640204 |
| Lethargy | 72.83 | 36.45 | 53 | 5337 | 81239 | 79657759 |
| Therapeutic product effect decreased | 72.32 | 36.45 | 71 | 5319 | 163792 | 79575206 |
| Feeling abnormal | 68.43 | 36.45 | 68 | 5322 | 159131 | 79579867 |
| Therapeutic product effect incomplete | 65.54 | 36.45 | 63 | 5327 | 141582 | 79597416 |
| Fatigue | 61.09 | 36.45 | 168 | 5222 | 929559 | 78809439 |
| Dizziness | 60.90 | 36.45 | 119 | 5271 | 526322 | 79212676 |
| Urticaria | 59.89 | 36.45 | 68 | 5322 | 185133 | 79553865 |
| Akathisia | 55.85 | 36.45 | 24 | 5366 | 13235 | 79725763 |
| Drug ineffective | 55.53 | 36.45 | 179 | 5211 | 1080734 | 78658264 |
| Adverse drug reaction | 47.77 | 36.45 | 38 | 5352 | 66354 | 79672644 |
| Depression | 46.72 | 36.45 | 65 | 5325 | 216725 | 79522273 |
| Gait disturbance | 44.39 | 36.45 | 62 | 5328 | 207444 | 79531554 |
| Salivary hypersecretion | 41.70 | 36.45 | 20 | 5370 | 14204 | 79724794 |
| Insomnia | 40.63 | 36.45 | 65 | 5325 | 245105 | 79493893 |
| Bradykinesia | 38.68 | 36.45 | 16 | 5374 | 8027 | 79730971 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N07XX13 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS OTHER NERVOUS SYSTEM DRUGS Other nervous system drugs |
| FDA MoA | N0000190855 | Vesicular Monoamine Transporter 2 Inhibitors |
| FDA EPC | N0000190856 | Vesicular Monoamine Transporter 2 Inhibitor |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Tardive dyskinesia | indication | 102449007 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.25 | Basic |
| pKa2 | 7.56 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
| EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Synaptic vesicular amine transporter | Transporter | INHIBITOR | Ki | 8.52 | DRUG LABEL | DRUG LABEL | |||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.77 | CHEMBL | |||||
| Synaptic vesicular amine transporter | Transporter | INHIBITOR | Ki | 6.73 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 54K37P50KH | UNII |
| 1639208-54-0 | SECONDARY_CAS_RN |
| 4036639 | VANDF |
| C4078701 | UMLSCUI |
| CHEMBL2364639 | ChEMBL_ID |
| 24795069 | PUBCHEM_CID |
| DB11915 | DRUGBANK_ID |
| D10675 | KEGG_DRUG |
| CHEMBL3707248 | ChEMBL_ID |
| 9744 | INN_ID |
| 8694 | IUPHAR_LIGAND_ID |
| 255701 | MMSL |
| 32624 | MMSL |
| d08559 | MMSL |
| 017167 | NDDF |
| 017168 | NDDF |
| 733727001 | SNOMEDCT_US |
| 763512007 | SNOMEDCT_US |
| 14580381 | PUBCHEM_CID |
| 1918219 | RXNORM |
| C000603978 | MESH_SUPPLEMENTAL_RECORD_UI |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1060 | CAPSULE | 60 mg | ORAL | NDA | 29 sections |
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1060 | CAPSULE | 60 mg | ORAL | NDA | 29 sections |
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1080 | CAPSULE | 80 mg | ORAL | NDA | 29 sections |
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1080 | CAPSULE | 80 mg | ORAL | NDA | 29 sections |
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-2040 | CAPSULE | 40 mg | ORAL | NDA | 29 sections |
| INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-2040 | CAPSULE | 40 mg | ORAL | NDA | 29 sections |